Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CN-105 for prevention of postoperative delirium and cognitive dysfunction
NCT03802396Phase 2Completed
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CN-105 in postoperative delirium (POD) and Post-operative cognitive dysfunction (POCD). Primary endpoint: Number of Adverse Events of Grade II or Higher Per Patient at 6 weeks. Started Jul 2018; status: completed.
02
Drugs
CN-105
03
Conditions
postoperative delirium (POD)Post-operative cognitive dysfunction (POCD)
Beyond the preview
Go deeper on NCT03802396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802396.